ReviewCurrent cardiology reports2026
The Intersection of Androgens and Cardiovascular Disease in Postmenopausal Women.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo summarize the current understanding of the relationships between endogenous and exogenous androgens and cardiovascular disease in postmenopausal women. RECENT
findingsEndogenous testosterone and dehydroepiandrosterone exhibit a J-shaped relationship with cardiovascular mortality. The association of exogenous testosterone with adverse cardiovascular outcomes is highly dependent on dose and route of administration. Non-oral testosterone administration is associated with neutral risks, but close monitoring of total testosterone levels is obligatory. Estrogen, progesterone, and androgens levels shift during menopause transition, and the ratios between levels have a greater impact on cardiometabolic and cardiovascular outcomes than absolute levels. While exogenous testosterone modestly improves hypoactive sexual desire, it is unknown if restoring testosterone levels to premenopausal physiologic conditions can also mitigate other age-related physical changes. Future studies addressing the timing, dose, route of administration, treatment duration, and combination therapy with estrogen in postmenopausal women of all racial and ethnicities are needed.
Indexed as
Identifiers
42573857What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.